Ai întrebări despre autism, ADHD, anxietate sau depresie? Găsești ghiduri clare, verificate de specialiști. Acum, acces gratuit.
Researchers developed a screening tool to improve timely referral of Parkinson's disease patients to specialized centers for device-aided therapies, based on analysis of 259 patients across 8 hospitals. The tool identified response fluctuations and dyskinesias as key predictors and outperformed existing 5-2-1 referral criteria in clinical decision-making.
A study of 486 LRRK2-PD and 9,259 idiopathic PD patients found that higher mitochondrial polygenic scores (related to mitochondrial function genes) were significantly associated with earlier disease onset in LRRK2-PD carriers. The research identified meaningful interactions between genetic risk and lifestyle factors (caffeinated soda in LRRK2-PD, tobacco use in idiopathic PD), suggesting that disease timing may be influenced by both genetic and modifiable environmental factors.
This research explores metabotropic glutamate receptors (mGluRs) as potential therapeutic targets for managing Parkinson's disease symptoms. The approach focuses on modulating glutamatergic signaling pathways to address motor dysfunction and neurodegeneration associated with the condition.
This preclinical study examined how intermittent theta-burst stimulation (iTBS), a noninvasive brain stimulation technique, modulates astrocyte function and glutamate homeostasis in a rat model of Parkinson's disease. Results showed iTBS improved striatal astrocyte responses, restored glutamate transporter function, and enhanced motor recovery, suggesting astrocyte modulation contributes to iTBS therapeutic effects.
This review examines advances in Parkinson's disease biomarkers, particularly α-synuclein detection using immunodetection and emerging seed amplification assays in cerebrospinal fluid and blood. Seed amplification assays show promise as more reliable diagnostic tools with improved accuracy, representing a significant advancement toward non-invasive biomarker testing for disease diagnosis and progression monitoring.